Maravai Lifesciences Holdings, Inc.
MRVI Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$7.32
KIRA · Stoqly’s AI analyst, in plain words
- Maravai Lifesciences Holdings, Inc. had $186M of revenue in fiscal 2025, down 28.3% on the year before. Over five years, revenue changed −8.1% a year on average.
- Its operating margin was −115.9%, down 25.0 pts: of every 100 in sales, about −116 is left after running the business.
- Maravai Lifesciences Holdings, Inc. lost $131M in fiscal 2025.
- Free cash flow was −$70.7M in fiscal 2025, −38.1% of revenue.
- Maravai Lifesciences Holdings, Inc. owes $106M more than it holds in cash.
Market cap
$1.1B
P/E
—
Revenue
$186M
Net income
−$131M
Free cash flow
−$70.7M
Operating margin
−115.9%
Maravai Lifesciences Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−28.3%
No. Sales fell 28.3% last year.
Does it make a profit?
−70.4%
No. It lost money last year.
Does profit turn into cash?
−38.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 9
Weak. It passes 1 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Maravai Lifesciences Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- MARAVAI LIFESCIENCES HOLDINGS, INC.
- CIK
- 0001823239
Maravai Lifesciences Holdings, Inc. · MRVI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $799M | $883M | $289M | $259M | $186M |
| Revenue growth | 181.3% | 10.5% | −67.3% | −10.3% | −28.3% |
| Gross margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.3% |
| Operating margin | 69.4% | 65.0% | −11.0% | −90.9% | −115.9% |
| Net income | $182M | $220M | −$119M | −$145M | −$131M |
| Net margin | 22.8% | 24.9% | −41.2% | −55.9% | −70.4% |
| Diluted EPS | $1.56 | $1.67 | −$0.90 | −$1.05 | −$0.90 |
| Cash | |||||
| Cash from operations | $369M | $536M | $126M | $7.5M | −$57.6M |
| Capital expenditure | $14.9M | $17.1M | $65.6M | $29.7M | $13.1M |
| Free cash flow | $354M | $519M | $60.7M | −$22.2M | −$70.7M |
| FCF margin | 44.3% | 58.8% | 21.0% | −8.6% | −38.1% |
| Share buybacks | $0.0M | $0.0M | — | — | — |
| Share count change | 791.8% | −1.0% | −48.3% | 4.5% | 4.7% |
| Debt and strength | |||||
| Cash and short-term investments | $551M | $632M | $575M | $322M | $217M |
| Debt incl. finance leases | $531M | $527M | $557M | $328M | $323M |
| Shareholders' equity | $315M | $545M | $417M | $325M | $212M |
| Net debt / EBITDA | −0.0x | −0.2x | — | — | — |
| Current ratio | 7.9x | 7.7x | 8.0x | 7.5x | 6.6x |
| Interest coverage | 18.3x | 28.1x | −0.7x | −4.9x | −8.0x |
| Returns and quality | |||||
| Return on capital | 166.3% | 116.0% | −5.6% | −62.3% | −59.2% |
| Return on equity | 90.1% | 51.2% | −24.7% | −39.0% | −48.6% |
| Return on tangible equity | 403.1% | 490.6% | — | — | — |
| Piotroski F-score | 8 | 6 | 4 | 4 | 1 |
| Altman Z'' | 4.7 | 4.8 | 3.8 | 2.1 | 0.9 |
Insiders bought, 12 months
$1.9M
2 insiders
Insiders sold, 12 months
$0.3M
1 insider
Of sales under plans
100%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Maravai Lifesciences Holdings, Inc. · MRVI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.32 a share, the company is worth $1.1B.
Source: SEC EDGAR XBRL filings (CIK 0001823239). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.